Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | PARL | Q9H300 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143334 | 0.75 | KDM4E (0.44) | MAPTSMN1; SMN2ALDH1A1MGLLPARL | |
| SCHEMBL2585788 | 0.73 | KDM4E (0.54) | MAPTSMN1; SMN2ALDH1A1KMT2AKDM4E | |
| SCHEMBL13056578 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1KMT2AHPGDKDM4E | |
| SCHEMBL4099973 | 0.73 | ALDH1A1 (0.48) | MAPTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL133554 | 0.71 | KMT2A (0.53) | MAPTSMN1; SMN2ALDH1A1MGLLPARL | |
| SCHEMBL19309377 | 0.71 | KMT2A (0.53) | MAPTSMN1; SMN2ALDH1A1MGLLPARL | |
| SCHEMBL8540066 | 0.70 | TSHR (0.50) | MAPTSMN1; SMN2ALDH1A1PARLHPGD | |
| SCHEMBL8861207 | 0.69 | TSHR (0.50) | MAPTSMN1; SMN2ALDH1A1KMT2AHPGD | |
| Acridine SCHEMBL7872845 | 0.69 | ALDH1A1 (0.46) | MAPTALDH1A1MGLLPARLKMT2A | |
| SCHEMBL28811993 | 0.69 | KDM4E (0.40) | MAPTSMN1; SMN2ALDH1A1MGLLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| EP-3276349-B1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3029461-B1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20140323336-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140323336-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8846320-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846320-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| WO-2012003476-A2 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003476-A2 | HAPTEN CONJUGATES FOR TARGET DETECTION | VENTANA MEDICAL SYSTEMS, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184087-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | MAPT 3454/4885SMN1; SMN2 4773/4885ALDH1A1 2096/4885 |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | MAPT 2927/4885SMN1; SMN2 4647/4885ALDH1A1 2734/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | MAPT 2915/4885SMN1; SMN2 4733/4885ALDH1A1 3347/4885 |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, AHR, RORB | MAPT 2927/4885SMN1; SMN2 4647/4885ALDH1A1 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.